MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s11523-026-01260-x

Медицинская библиотека · Targeted oncology · 2026

Adjuvant Systemic Therapies After Nephrectomy for Renal Cell Carcinoma: A Bayesian Network Meta-Analysis and Multi-Criteria Benefit-Risk Assessment.

Yajima Shugo, Okumura Gaku, Yoshida Soichiro, Fukushima Hiroshi, Sato Hiroyuki, Hirakawa Akihiro, Kijima Toshiki, Masuda Hitoshi, Fujii Yasuhisa

СтатьяСистематический обзорПеревод пока не подготовлен

Аннотация

BACKGROUND

Adjuvant pembrolizumab has improved disease-free survival after nephrectomy for high-risk renal cell carcinoma, and pembrolizumab plus belzutifan has further expanded the treatment landscape.

OBJECTIVE

We compared efficacy and treatment burden across adjuvant systemic therapies and examined the benefit-risk trade-off of the combination.

METHODS

Randomized trials of systemic therapy after nephrectomy were synthesized using a Bayesian network meta-analysis. Disease-free survival hazard ratios were converted to illustrative 2-year estimates using a common pembrolizumab baseline. Observed differences in 2-year disease-free survival, grade 3 or higher adverse events, and treatment discontinuation came from LITESPARK-022. Using these data, a multi-criteria decision analysis examined how outcome weighting affected the balance between the two regimens.

RESULTS

Six randomized datasets formed a tree-shaped network of eight regimens. In LITESPARK-022, adding belzutifan yielded approximately seven additional disease-free patients per 100 treated, but also approximately 22 additional patients with grade 3 or higher adverse events and 15 additional treatment discontinuations. Under the primary decision-analytic assumptions, the combination had the higher net-benefit score only when disease-free survival received roughly two thirds of the decision weight (threshold 0.68; range 0.47-0.79 across sensitivity analyses). Most comparisons relied on a single dataset, and overall survival and patient-reported outcomes remained immature.

CONCLUSIONS

Adding belzutifan to pembrolizumab improved disease-free survival but increased toxicity and treatment discontinuation. The decision analysis illustrates a model-dependent trade-off rather than identifying a preferred regimen. Because overall survival data are immature, the decision to intensify treatment remains risk and preference sensitive.

PROSPERO REGISTRATION: CRD420261454205.

Для цитирования: Yajima Shugo, Okumura Gaku, Yoshida Soichiro, Fukushima Hiroshi, Sato Hiroyuki, Hirakawa Akihiro, Kijima Toshiki, Masuda Hitoshi, Fujii Yasuhisa. Adjuvant Systemic Therapies After Nephrectomy for Renal Cell Carcinoma: A Bayesian Network Meta-Analysis and Multi-Criteria Benefit-Risk Assessment.. Targeted oncology. 2026. DOI: 10.1007/s11523-026-01260-x.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.